U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07759596) titled 'Bridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital' on Feb. 23.
Brief Summary: Study 1: Cost-effectiveness of TAK-003 Dengue Vaccination in Thailand
This study aims to evaluate the cost-effectiveness of introducing the live-attenuated tetravalent dengue vaccine (TAK-003) into Thailand's national immunization program. The study will compare routine vaccination strategies targeting two high-risk age groups: older children aged 9-14 years and adolescents/young adults aged 15-24 years, to identify the most appropriate target population for national implementation....